Eli Lilly and Co. and Purdue University on Thursday announced a strategic five-year agreement—the biggest in Purdue’s history with a biopharma, under which Lilly will provide as much as $52 million to develop improved delivery of injectable medicines to reduce pain, number of injections, and improve patient compliance.
The collaboration will also focus on developing predictive models for clinical trials that reduce risks associated with investing in drug development and perhaps more effectively predict the outcome of new therapies in humans.
Purdue researchers from the natural and physical sciences, engineering and veterinary medicine will contribute to the interdisciplinary collaboration with Lilly researchers.
“Purdue has enjoyed a long histo
“The biomedical revolution is upon us, but harnessing its full potential will require strong collaboration between academic research centers and industry partners,” said David Ricks, Lilly’s chairman, president and chief executive officer. “We look forward to expanding our relationship with Purdue as we work together to discover breakthrough solutions for patients.”
The collaboration intends to expand to other areas to further leverage the range of expertise at the two institutions.
